- Home
- EPM vs SCLXW Comparison
EPM vs SCLXW Comparison
Compare EPM & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPM
- SCLXW
- Stock Information
- Founded
- EPM 2003
- SCLXW N/A
- Country
- EPM United States
- SCLXW United States
- Employees
- EPM N/A
- SCLXW N/A
- Industry
- EPM Oil & Gas Production
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- EPM Energy
- SCLXW Health Care
- Exchange
- EPM Nasdaq
- SCLXW Nasdaq
- Market Cap
- EPM N/A
- SCLXW N/A
- IPO Year
- EPM 1996
- SCLXW N/A
- Fundamental
- Price
- EPM $5.13
- SCLXW $0.11
- Analyst Decision
- EPM Strong Buy
- SCLXW
- Analyst Count
- EPM 2
- SCLXW 0
- Target Price
- EPM $7.38
- SCLXW N/A
- AVG Volume (30 Days)
- EPM 162.0K
- SCLXW 4.0K
- Earning Date
- EPM 02-11-2025
- SCLXW 03-07-2025
- Dividend Yield
- EPM 9.36%
- SCLXW N/A
- EPS Growth
- EPM N/A
- SCLXW N/A
- EPS
- EPM 0.04
- SCLXW N/A
- Revenue
- EPM $86,423,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- EPM $7.51
- SCLXW N/A
- Revenue Next Year
- EPM N/A
- SCLXW N/A
- P/E Ratio
- EPM $122.86
- SCLXW N/A
- Revenue Growth
- EPM N/A
- SCLXW 22.02
- 52 Week Low
- EPM $4.59
- SCLXW $0.18
- 52 Week High
- EPM $6.29
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- EPM 39.28
- SCLXW N/A
- Support Level
- EPM $5.18
- SCLXW N/A
- Resistance Level
- EPM $5.32
- SCLXW N/A
- Average True Range (ATR)
- EPM 0.14
- SCLXW 0.00
- MACD
- EPM -0.02
- SCLXW 0.00
- Stochastic Oscillator
- EPM 29.55
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.